ALAMEDA, Calif--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) will host a conference call, which will be simultaneously webcast, on Thursday, June 7th, at 1:00PM ET. The purpose of the call is to discuss recent company developments. Among the topics to be discussed is the Company’s entry into a Letter of Intent to purchase Mytogen, Inc. and its Myoblast Program for the treatment of heart failure, and its plans to commence Phase II human clinical trials to treat heart failure using Mytogen’s Autologous Myoblast Stem Cell Therapy.
